Login / Signup

Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression.

Jaskaren KohliChen GeEleni FitsiouMiriam DoepnerSimone M BrandenburgWilliam James FallerTodd W RidkyMarco Demaria
Published in: Nature communications (2022)
Human melanocytic nevi (moles) result from a brief period of clonal expansion of melanocytes. As a cellular defensive mechanism against oncogene-induced hyperplasia, nevus-resident melanocytes enter a senescent state of stable cell cycle arrest. Senescent melanocytes can persist for months in mice and years in humans with a risk to escape the senescent state and progress to melanoma. The mechanisms providing prolonged survival of senescent melanocytes remain poorly understood. Here, we show that senescent melanocytes in culture and in nevi express high level of the anti-apoptotic BCL-2 family member BCL-W but remain insensitive to the pan-BCL-2 inhibitor ABT-263. We demonstrate that resistance to ABT-263 is driven by mTOR-mediated enhanced translation of another anti-apoptotic member, MCL-1. Strikingly, the combination of ABT-263 and MCL-1 inhibitors results in synthetic lethality to senescent melanocytes, and its topical application sufficient to eliminate nevi in male mice. These data highlight the important role of redundant anti-apoptotic mechanisms for the survival advantage of senescent melanocytes, and the proof-of-concept for a non-invasive combination therapy for nevi removal.
Keyphrases
  • cell death
  • cell cycle arrest
  • endothelial cells
  • cell proliferation
  • oxidative stress
  • cancer therapy
  • electronic health record
  • big data
  • insulin resistance
  • deep learning
  • wild type